LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

FibroGen Inc

Suletud

SektorTervishoid

0.31 3.33

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.29

Max

0.32

Põhinäitajad

By Trading Economics

Sissetulek

-13M

4.6M

Müük

126M

2.7M

Aktsiakasum

0.05

Kasumimarginaal

169.368

Töötajad

225

EBITDA

77M

-14M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+3233.33% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-1.1M

30M

Eelmine avamishind

-3.02

Eelmine sulgemishind

0.31

Uudiste sentiment

By Acuity

56%

44%

327 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

FibroGen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. veebr 2025, 11:34 UTC

Omandamised, ülevõtmised, äriostud

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20. veebr 2025, 11:34 UTC

Omandamised, ülevõtmised, äriostud

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20. veebr 2025, 11:33 UTC

Omandamised, ülevõtmised, äriostud

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20. veebr 2025, 11:33 UTC

Omandamised, ülevõtmised, äriostud

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20. veebr 2025, 11:31 UTC

Omandamised, ülevõtmised, äriostud

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20. veebr 2025, 11:30 UTC

Omandamised, ülevõtmised, äriostud

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

Võrdlus sarnastega

Hinnamuutus

FibroGen Inc Prognoos

Hinnasiht

By TipRanks

3233.33% tõus

12 kuu keskmine prognoos

Keskmine 10 USD  3233.33%

Kõrge 10 USD

Madal 10 USD

Põhineb 2 Wall Streeti analüütiku instrumendi FibroGen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.306 / 0.33939Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

327 / 380 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest FibroGen Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.